Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors

Overview

Journal Cancer Res

Specialty Oncology

Date 2016 Dec 25

PMID 28011623

Citations 6

Authors

Joseph W Wragg

Victoria L Heath

Roy Bicknell

Affiliations

Soon will be listed here.

Abstract

Antiangiogenic therapies have failed to confer survival benefits in patients with metastatic breast cancer (mBC). However, to date, there has not been an inquiry into the roles for acquired versus innate drug resistance in this setting. In this study, we report roles for these distinct phenotypes in determining therapeutic response in a murine model of mBC resistance to the antiangiogenic tyrosine kinase inhibitor sunitinib. Using tumor measurement and vascular patterning approaches, we differentiated tumors displaying innate versus acquired resistance. Bioluminescent imaging of tumor metastases to the liver, lungs, and spleen revealed that sunitinib administration enhances metastasis, but only in tumors displaying innate resistance to therapy. Transcriptomic analysis of tumors displaying acquired versus innate resistance allowed the identification of specific biomarkers, many of which have a role in angiogenesis. In particular, aquaporin-1 upregulation occurred in acquired resistance, mTOR in innate resistance, and pleiotrophin in both settings, suggesting their utility as candidate diagnostics to predict drug response or to design tactics to circumvent resistance. Our results unravel specific features of antiangiogenic resistance, with potential therapeutic implications. .

Citing Articles

Network-Derived Radioresistant Breast Cancer Target with Candidate Inhibitors from Brown Algae: A Sequential Assessment from Target Selection to Quantum Chemical Calculation.

Sivakumar M, Ahmad S, Emran T, Angulo-Bejarano P, Sharma A, Ahmed S Mar Drugs. 2023; 21(10).

PMID: 37888480 PMC: 10608582. DOI: 10.3390/md21100545.

Dual-Functional Polymeric Micelles Co-Loaded with Antineoplastic Drugs and Tyrosine Kinase Inhibitor for Combination Therapy in Colorectal Cancer.

Shih Y, Peng C, Chiang P, Shieh M Pharmaceutics. 2022; 14(4).

PMID: 35456602 PMC: 9030189. DOI: 10.3390/pharmaceutics14040768.

Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway.

Li L, Zhao S, Liu Z, Zhang N, Pang S, Liu J Cell Death Dis. 2021; 12(2):220.

PMID: 33637706 PMC: 7910457. DOI: 10.1038/s41419-021-03511-3.

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.

Wang D, Xiao F, Feng Z, Li M, Kong L, Huang L Breast Cancer Res. 2020; 22(1):103.

PMID: 32993785 PMC: 7526390. DOI: 10.1186/s13058-020-01346-y.

Ginsenoside Rg3: Potential Molecular Targets and Therapeutic Indication in Metastatic Breast Cancer.

Nakhjavani M, Hardingham J, Palethorpe H, Tomita Y, Smith E, Price T Medicines (Basel). 2019; 6(1).

PMID: 30678106 PMC: 6473622. DOI: 10.3390/medicines6010017.

References

Ebos J, Lee C, Christensen J, Mutsaers A, Kerbel R . Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007; 104(43):17069-74. PMC: 2040401. DOI: 10.1073/pnas.0708148104. View

Barrios C, Liu M, Lee S, Vanlemmens L, Ferrero J, Tabei T . Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010; 121(1):121-31. PMC: 2855860. DOI: 10.1007/s10549-010-0788-0. View

Yin T, He S, Ye T, Shen G, Wan Y, Wang Y . Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis. Transl Oncol. 2014; 7(2):221-9. PMC: 4101341. DOI: 10.1016/j.tranon.2014.02.007. View

Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P . Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008; 26(11):1810-6. DOI: 10.1200/JCO.2007.14.5375. View

Bergers G, Hanahan D . Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8):592-603. PMC: 2874834. DOI: 10.1038/nrc2442. View

Radulovic S, Bjelogrlic S . Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON. 2007; 12 Suppl 1:S151-62. View

Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga J . Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(12):1351-60. DOI: 10.1016/S1470-2045(14)70444-9. View

Fang L, Lee V, Cha E, Zhang H, Hwang S . CCR7 regulates B16 murine melanoma cell tumorigenesis in skin. J Leukoc Biol. 2008; 84(4):965-72. PMC: 2538602. DOI: 10.1189/jlb.1107776. View

Guo T, Hajdu M, Agaram N, Shinoda H, Veach D, Clarkson B . Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res. 2009; 15(22):6862-70. PMC: 2783687. DOI: 10.1158/1078-0432.CCR-09-1315. View

10.

Bergh J, Bondarenko I, Lichinitser M, Liljegren A, Greil R, Voytko N . First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012; 30(9):921-9. DOI: 10.1200/JCO.2011.35.7376. View

11.

Patel N, Li J, Generali D, Poulsom R, Cranston D, Harris A . Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005; 65(19):8690-7. DOI: 10.1158/0008-5472.CAN-05-1208. View

12.

Tsuzuki T, Okada H, Cho H, Shimoi K, Miyashiro H, Yasuda K . Divergent regulation of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor by hypoxia and female sex steroids in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol. 2013; 168(1):95-101. DOI: 10.1016/j.ejogrb.2012.12.040. View

13.

MAUNSBACH A, Marples D, Chin E, Ning G, BONDY C, Agre P . Aquaporin-1 water channel expression in human kidney. J Am Soc Nephrol. 1997; 8(1):1-14. DOI: 10.1681/ASN.V811. View

14.

Okazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, Yamaya M . Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol. 2005; 18(1):1-9. DOI: 10.1093/intimm/dxh334. View

15.

Kerbel R . Reappraising antiangiogenic therapy for breast cancer. Breast. 2011; 20 Suppl 3:S56-60. PMC: 4540338. DOI: 10.1016/S0960-9776(11)70295-8. View

16.

Sakai I, Miyake H, Fujisawa M . Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int. 2013; 112(2):E211-20. DOI: 10.1111/j.1464-410X.2012.11655.x. View

17.

Guerin E, Man S, Xu P, Kerbel R . A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 2013; 73(9):2743-8. PMC: 4334448. DOI: 10.1158/0008-5472.CAN-12-4183. View

18.

Crown J, Dieras V, Staroslawska E, Yardley D, Bachelot T, Davidson N . Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013; 31(23):2870-8. DOI: 10.1200/JCO.2012.43.3391. View

19.

Collet G, Lamerant-Fayel N, Tertil M, El Hafny-Rahbi B, Stepniewski J, Guichard A . Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol Cancer Ther. 2013; 13(1):165-78. PMC: 3893111. DOI: 10.1158/1535-7163.MCT-13-0637. View

20.

Welti J, Powles T, Foo S, Gourlaouen M, Preece N, Foster J . Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis. 2012; 15(4):623-41. PMC: 3496518. DOI: 10.1007/s10456-012-9291-z. View